CN113712921A - Novel rapid local pain-relieving hemostatic and application thereof - Google Patents
Novel rapid local pain-relieving hemostatic and application thereof Download PDFInfo
- Publication number
- CN113712921A CN113712921A CN202111046417.8A CN202111046417A CN113712921A CN 113712921 A CN113712921 A CN 113712921A CN 202111046417 A CN202111046417 A CN 202111046417A CN 113712921 A CN113712921 A CN 113712921A
- Authority
- CN
- China
- Prior art keywords
- hemostatic
- relieving
- pain
- novel rapid
- trans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Rheumatology (AREA)
Abstract
The invention discloses a novel rapid local pain-relieving hemostatic and application thereof, and relates to the technical field of medical hemostasis. The analgesic hemostatic consists of the following components in percentage by weight: 85-99% of fluorohydrocarboned compound, 1-15% of hemostatic component and 0-15% of medical auxiliary material, wherein the fluorohydrocarboned compound is a mixture of 1, 1, 1-3, 3-pentafluoropropane-245 fa, R134 a-tetrafluoroethane, trans-1, 3, 3, 3-tetrafluoro-1-propylene-1234 ze and trans-1-chloro-3, 3, 3-trifluoropropene-1233 zd, and the hemostatic component is norepinephrine or epinephrine. The spray form of spray administration is applied to quick short-term pain relief and hemostasis on the skin, the complete mucous membrane and the surface of an open small wound in medicine, can quickly take effect, relieve pain in a short time, stop bleeding instantly, reduce the amount of bleeding, and has higher use safety and wide application prospect.
Description
Technical Field
The invention relates to the technical field of medical hemostasis, in particular to a novel rapid local pain-relieving hemostatic and application thereof in emergency short-term rapid pain relieving and hemostasis on the surface of small open wounds of skin and mucosa.
Background
For small hemorrhagic trauma (non-internal hemorrhage, non-active and venous hemorrhage) caused by natural disasters, daily accidents, war and the like and small wound surgery of skin and mucous membranes, patients need to be rapidly subjected to pain relieving and bleeding stopping at the wound site, and then sutured, treated or transferred to medical institutions for treatment. The timely pain and bleeding stopping can bring better feeling to the psychology and the body of the wounded, and is also beneficial to the medical care personnel to deal with the wounded condition in time.
However, in clinical medicine, in case of the above situations, the conventional method is to utilize the analgesic to relieve pain, and then use the wiping hemostasia and hemostatics to stop bleeding, so that the effects of quickly relieving pain and stopping blood and nursing wounds cannot be achieved, and meanwhile, the infection probability, the complicated operation, the fibrous tissue hyperplasia and the drug metabolic reaction are reduced, and the better hemostatic effect is achieved.
The commonly used hemostasis methods and medicines in the market at present are as follows:
1. medicine for stopping bleeding
(1) Hemostatic medicine acting on blood vessels
Hypophysin: bleeding due to esophageal and gastric varices rupture, ulcer, acute gastric mucosa injury and cardia mucosa laceration.
② norepinephrine: acting on arterioles and capillaries of gastrointestinal mucosa to make them strongly contract.
③ somatostatin: upper gastrointestinal hemorrhage, pancreatitis and dyspepsia. Carbachol/carbazochrome sodium: epistaxis, uterine bleeding, cerebral hemorrhage, etc.
Phenolsulfoethylamine: prevent hemorrhage before and after operation, gastrointestinal hemorrhage, etc.
(2) Anti-fibrinolytic agents
Tranexamic acid: treating hemorrhage due to hyperfibrinolysis and severe hemorrhage due to excessive thrombolysis.
(3) Thrombin
Thrombin: local hemostasis due to small blood vessels or capillary blood leakage, traumatic hemorrhage, and hemorrhage of upper digestive tract after oral administration.
② prothrombin complex: bleeding due to deficiency of blood coagulation factors, diphacinone sodium poisoning.
③ venom hemocoagulase: various medical conditions are needed to reduce bleeding or hemostasis.
(4) Medicine for promoting blood coagulation factor activation
Vitamin K1: hemorrhagic diseases of newborn, biliary colic, etc.
2. Tourniquets, compression methods, and the like are used for arterial and venous bleeding and are not suitable for emergency treatment of small wounds.
At the first time of wound occurrence, the above methods either fail to achieve hemostasis the first time, or are inconvenient to achieve hemostasis the fastest at the first time. For example, the methods of injecting the analgesic first and then performing compression hemostasis, ligation hemostasis, packing hemostasis and the like are time-consuming and labor-consuming, and are not suitable for simultaneous pain relieving and hemostasis treatment of local wounds and minor operations of skin, mucosa and the like. The use of the external hemostatic is also not beneficial for doctors to treat the wound surface and carry out subsequent wound surface repair and operation; the action time and hemostatic effect of the injection or oral hemostatic are too long, the hemostatic problem cannot be solved at the first time, and the risks of drug metabolism and adverse reactions also exist.
Many fluorinated hydrocarbon compounds are gases at normal temperature and pressure, and are generally high-pressure gases and liquefied gases. In industry, the compounds have a great number of applications, such as refrigerants, foaming agents, cleaning agents, pesticide aids and the like, and can also be used as a propelling component of a medical disinfectant. Based on the relation between peripheral blood vessel contraction and wound surface and tissue temperature, the peripheral blood vessels contract to stop bleeding at the temperature of between 2 ℃ below zero and 4 ℃ below zero, in recent years, liquid nitrogen and liquid carbon dioxide are clinically applied, but deep freezing is caused by the low refrigeration temperature of the liquid nitrogen and the liquid carbon dioxide, and strong adverse reactions are accompanied, such as delayed edema, exudation, blood blister, bleeding, chronic ulcer, hypertrophic scar and unhealed sore surface, and local nerve dysfunction and the like of individual patients can occur. It is especially not suitable for treating affected parts such as face and skin. Based on the above, the development of a novel rapid local pain-relieving hemostatic and the application thereof are particularly necessary.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide a novel rapid local pain-relieving hemostatic and application thereof, which are convenient to use, can be locally applied to skin, complete mucous membrane and small open wound, can quickly take effect, relieve pain for a short time, stop bleeding instantly, reduce bleeding amount, have higher use safety and are easy to popularize and use.
In order to achieve the purpose, the invention is realized by the following technical scheme: a novel rapid local pain-relieving hemostatic agent comprises the following components in percentage by weight: 85-99% of fluorohydrocarbonic compounds, 1-15% of hemostatic components and 0-15% of medical auxiliary materials.
Preferably, the hydrocarbon compound to be fluorohydrogenated includes 1, 1, 1-3, 3-pentafluoropropane-245 fa, R134 a-tetrafluoroethane, trans-1, 3, 3, 3-tetrafluoro-1-propene-1234 ze, trans-1-chloro-3, 3, 3-trifluoropropene-1233 zd.
Preferably, the hemostatic component is norepinephrine or epinephrine.
Preferably, the medical auxiliary material adopts nitrogen or ethanol.
Preferably, the hemostatic agent preferably has the following formula in percentage by weight: 90-99% of fluorohydrogenate hydrocarbon compounds and 1-10% of hemostatic components.
The application of the novel rapid local pain-relieving hemostatic agent is in the form of spray for administration by spraying, and the novel rapid local pain-relieving hemostatic agent is applied to rapidly relieve pain and stop bleeding on the surfaces of skin, intact mucous membranes and small open wounds in a short time in medicine.
Preferably, the spray of the analgesic hemostatic is in the form of a mist.
The invention has the beneficial effects that: the rapid local pain-relieving hemostatic for emergency use provided by the invention is convenient to use, can be applied to the medical field to achieve rapid local pain-relieving hemostasis on skin, mucosa and small open wounds, can take effect quickly, relieve pain for a short time, stop bleeding instantly, reduce the amount of bleeding, has higher use safety, gains more opportunities for subsequent treatment of wounds, provides a better treatment environment for patients and has wide application prospect.
Detailed Description
In order to make the technical means, the creation characteristics, the achievement purposes and the effects of the invention easy to understand, the invention is further described with the specific embodiments.
The specific implementation mode adopts the following technical scheme: a novel rapid local pain-relieving hemostatic agent comprises the following components in percentage by weight: 85-99% of fluorohydrocarbonic compounds, 1-15% of hemostatic components and 0-15% of medical auxiliary materials.
It is noted that the preferred formulation of the hemostatic agent in weight percent is: 90-99% of fluorohydrogenate hydrocarbon compounds and 1-10% of hemostatic components.
In addition, the hemostatic component adopts noradrenaline or adrenaline; the medical auxiliary materials adopt nitrogen or ethanol, and a proper amount of medical auxiliary materials can be added according to the administration form and the requirements of products.
In this embodiment, as the hydrocarbon compound to be subjected to fluorohydrogenation, 1, 1, 1-3, 3-pentafluoropropane-245 fa, R134 a-tetrafluoroethane, trans-1, 3, 3, 3-tetrafluoro-1-propene-1234 ze, trans-1-chloro-3, 3, 3-trifluoropropene-1233 zd are used. Of the formula CF3CH2CHF2Chemical Abstract number (CAS No.) 460-73-1. Under normal pressure, the solution is colorless liquid at 15 ℃, the saturated vapor pressure (20 ℃) is 122.7KPa, the liquid density (20 ℃) is 1.32g/ml, the solution is colorless gas at 20 ℃, and the solubility in water (the pH is 8.11-8.62 and the room temperature) is 7180 mg/L. The 1, 1, 1-3, 3-pentafluoropropane-245 fa, R134 a-tetrafluoroethane, trans-1, 3, 3, 3-tetrafluoro-1-propene-1234 ze, trans-1-chloro-3, 3, 3-trifluoropropene-1233 zd are non-toxic, non-flammable, do not destroy the ozone layer, have short retention time in the atmosphere, have little influence on the environment, have stable chemical properties and have obvious advantages. Wherein, the 1, 1, 1-3, 3-pentafluoropropane-245 fa, the trans-1-chloro-3, 3, 3-trifluoropropene-1233 zd is mainly applied to foaming agents, such as rigid polyurethane and polyisocyanurate foams, insulating plastic foams, thermal insulation material foams and the like, the 1, 1, 1-3, 3-pentafluoropropane-245 fa, the trans-1-chloro-3, 3, 3-trifluoropropene-1233 zd in the industrial field can be used as a refrigerant independently or matched with other components, and the R134 a-tetrafluoroethane, the trans-1, 3, 3, 3-tetrafluoro-1-propene-1234 ze is mainly applied to the refrigerants, propellants, thermal insulation material foams and the like.
The specific embodiment has the advantages that 1, 1, 1-3, 3-pentafluoropropane-245 fa, R134 a-tetrafluoroethane, trans-1, 3, 3, 3-tetrafluoro-1-propene-1234 ze and trans-1-chloro-3, 3, 3-trifluoropropene-1233 zd are applied to hemostasis in the medical field in a breakthrough mode. The cooling can play the role of a hemostatic, namely 1, 1, 1-3, 3-pentafluoropropane-245 fa and trans-1-chloro-3, 3, 3-trifluoropropene-1233 zd are mainly used as hemostatic sources of the spraying agent at the liquefaction temperature, can be rapidly evaporated on the surface of the tissue so as to reduce the temperature of the tissue area and enable peripheral blood vessels to contract, and the effect can be continued for a certain time to immediately generate the hemostatic effect. R134 a-tetrafluoroethane, trans-1, 3, 3, 3-tetrafluoro-1-propene-1234 ze are mainly used as the spraying power source of the spray at the liquefaction temperature, and simultaneously, the R134 a-tetrafluoroethane, trans-1, 1-3, 3-pentafluoropropane-245 fa and trans-1-chloro-3, 3, 3-trifluoropropene-1233 zd generate a synergistic effect, the mixture of the R134 a-tetrafluoroethane, the trans-1, 1-3, 3-pentafluoropropane-245 fa and the trans-1-chloro-3, 3, 3-trifluoropropene-1233 zd forms a low evaporation rate, and the mixture is dispersed on the surface of the skin through a special release system and is immediately evaporated to form an instant sub-freezing cooling effect, so that peripheral blood vessels are shrunk, thereby achieving the effects of relieving pain and stopping bleeding without causing nerve injury and other adverse reactions.
The 1, 1, 1-3, 3-pentafluoropropane-245 fa, R134 a-tetrafluoroethane, trans-1, 3, 3, 3-tetrafluoro-1-propene-1234 ze, trans-1-chloro-3, 3, 3-trifluoropropene-1233 zd, hemostatic components, etc. used in the present embodiment all meet medically acceptable standards and are commercially available. During production, the raw materials are mixed in proportion, enter a container through a valve, are subjected to pressure filling, are sealed and are subjected to leakage detection.
The application of the novel rapid local pain-relieving hemostatic agent is in the form of spray for administration by spraying, and the novel rapid local pain-relieving hemostatic agent is applied to rapidly relieve pain and stop bleeding on the surfaces of skin, intact mucous membranes and small open wounds in a short time in medicine. The spray of the pain-relieving hemostatic is in a mist type.
In view of the above description, the present embodiment performs matching of four formulas and corresponding hemostasis experiments.
(1) The analgesic hemostatic is prepared by matching four formulas, and the formula composition is shown in table 1:
TABLE 1 prescription of four groups of analgesic hemostatic
The obtained mist type spray for relieving pain and stopping bleeding is used, the tank body is held by hands, and the brake button is pressed down forcefully at a proper distance from the treatment position, so that the mist is sprayed out of the tank. The specific application method is as follows according to different clinical conditions:
non-great vessel skin hemorrhagic trauma: the treatment area is wiped with disinfectant and sprayed from 5-20 cm away from the treatment area for about 5-15 seconds. Relieving pain for 15-30 min, stopping bleeding for several seconds to 3 min, and treating wound such as cleaning wound, suturing, and dressing. The operation is repeated again as necessary.
② local anesthesia in minor surgery: the area of treatment was wiped with disinfectant, the adjacent area protected with petrolatum and sprayed from a distance of 5-20 cm from the area of treatment for approximately 4-15 seconds. Cutting rapidly, relieving pain for 15-30 min, stopping bleeding for several seconds to 3 min, and repeating the operation as required.
③ mucosa hemostasis: when the spray is used for mucosa operation or wound hemostasis, a can body of the spray is held by hands, and the spray is sprayed from a special nozzle for mucosa at a short distance of 5-15cm through a mucosa nozzle, so that the fluid can meet the requirement of the mucosa to reduce the influence of fluid impact. Spraying directly until the whole mucous membrane is covered, the value of the spray scanning is determined by the area of the mucous membrane, cooling the mucous membrane by spraying, and if necessary, gradually increasing the intensity of the continuous scanning.
(2) Evaluation of hemostatic Properties
Animals: male and female rats, meeting the pharmaceutical clinical laboratory criteria, were used, weighing between 200g and 300 g.
② local skin and small wound hemostasis experiment: divided into experimental and control groups. The products obtained by the formulas of the above embodiments sequentially correspond to a group of experiments, wherein the hemostasis part implemented by the experiments is the back of a rat, and the spray is in a mist type. 3 doses were administered to each animal, 2 animals were used for each test, and the values listed in table 2 below are mean values. To evaluate the hemostatic effect, a one centimeter long incision-a deep muscle layer, referred to as "incision" in the table, was made with a scalpel at each application point, and when local bleeding (vasoconstrictive state) of the skin was observed after the incision, the site was considered to be non-analgesic, hemostatic, i.e., painful, bleeding evident. The time evaluated 5 seconds is the test unit.
TABLE 2 comparison table for hemostasis experiment
The experiments show that the traditional Chinese medicine composition has local pain relieving and bleeding stopping effects on the surface of the skin of an animal, and under the effective dose, the pain relieving time is not less than 30min, and the bleeding stopping time is not less than 5 seconds.
The mist type spray adopted by the embodiment can be used as an auxiliary treatment means for rapidly relieving pain and stopping bleeding of small non-internal hemorrhagic wounds, and the action time is enough for relieving pain and stopping bleeding of wounds such as suturing and bandaging. The application method comprises spraying the composition from 5-20 cm to the treatment area, and the composition has analgesic effect lasting for several minutes to 30 minutes, hemostatic effect lasting for several minutes to 5 seconds to 3 minutes, and can be repeated as required.
The specific implementation mode can be locally applied to skin, complete mucous membranes such as oral cavities, nasal passages, lips and the like and small open wounds, is convenient to use, can effectively control pain and bleeding caused by wounds and minor operations, quickly takes effect, relieves pain for a short time, instantly stops bleeding and reduces the bleeding amount. The hemostatic is used for controlling pain and hemostasis caused by injection (such as cosmetic surgery and the like), minor surgery (such as removal of furuncle, pus discharge, needle sewing and the like), traumatic bleeding treatment and the like, can be used for rapid local hemostasis of skin, mucosa and open small wounds in medicine, has good hemostasis effect and excellent use safety, can win more opportunities for subsequent treatment of the wounds and provide better treatment environment for patients, and has wide market application prospect.
The foregoing shows and describes the general principles and broad features of the present invention and advantages thereof. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (7)
1. A novel rapid local pain-relieving hemostatic agent is characterized by comprising the following components in percentage by weight: 85-99% of fluorohydrocarbonic compounds, 1-15% of hemostatic components and 0-15% of medical auxiliary materials.
2. A novel rapid topical analgesic haemostatic agent according to claim 1 characterised in that the fluorohydrogenate hydrocarbon compound is 1, 1, 1-3, 3-pentafluoropropane-245 fa, R134 a-tetrafluoroethane, trans-1, 3, 3, 3-tetrafluoro-1-propene-1234 ze, trans-1-chloro-3, 3, 3-trifluoropropene-1233 zd.
3. The novel rapid topical analgesic hemostatic agent according to claim 1, wherein the hemostatic component is norepinephrine or epinephrine.
4. The novel rapid topical analgesic hemostatic agent according to claim 1, wherein the medical excipient is nitrogen or ethanol.
5. A novel rapid local analgesic haemostat according to claim 1, characterised in that the preferred formulation of the haemostat is, in weight percent: 90-99% of fluorohydrogenate hydrocarbon compounds and 1-10% of hemostatic components.
6. The application of the novel rapid local pain-relieving hemostatic is characterized in that the pain-relieving hemostatic is applied to the skin, the intact mucous membrane and the surface of an open small wound in medicine in the form of spray for spray administration to rapidly relieve pain and stop bleeding for a short time.
7. The use of a novel rapid topical analgesic haemostatic agent according to claim 6, characterised in that the spray of analgesic haemostatic agent is in the form of a mist.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111046417.8A CN113712921A (en) | 2021-09-02 | 2021-09-02 | Novel rapid local pain-relieving hemostatic and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111046417.8A CN113712921A (en) | 2021-09-02 | 2021-09-02 | Novel rapid local pain-relieving hemostatic and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113712921A true CN113712921A (en) | 2021-11-30 |
Family
ID=78682426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111046417.8A Pending CN113712921A (en) | 2021-09-02 | 2021-09-02 | Novel rapid local pain-relieving hemostatic and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113712921A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709507A (en) * | 2005-06-29 | 2005-12-21 | 肖春 | External-application compound hemostatic analgesia anti-inflammation medicine |
| CN106361730A (en) * | 2015-07-23 | 2017-02-01 | 珠海和凡医药股份有限公司 | New uses of pentafluoropropane as medical condensing agent in local anesthesia, pain stopping and swelling subsiding |
| CN107198682A (en) * | 2016-03-17 | 2017-09-26 | 沈阳宜事达医药科技有限公司 | A kind of refrigerant anesthetic and its application |
-
2021
- 2021-09-02 CN CN202111046417.8A patent/CN113712921A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709507A (en) * | 2005-06-29 | 2005-12-21 | 肖春 | External-application compound hemostatic analgesia anti-inflammation medicine |
| CN106361730A (en) * | 2015-07-23 | 2017-02-01 | 珠海和凡医药股份有限公司 | New uses of pentafluoropropane as medical condensing agent in local anesthesia, pain stopping and swelling subsiding |
| CN107198682A (en) * | 2016-03-17 | 2017-09-26 | 沈阳宜事达医药科技有限公司 | A kind of refrigerant anesthetic and its application |
Non-Patent Citations (1)
| Title |
|---|
| 李立安, 河北科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bilgili et al. | Hemostatic efficacy of Ankaferd Blood Stopper® in a swine bleeding model | |
| CA2595132C (en) | Agents for controlling biological fluids and methods of use thereof | |
| US9168325B2 (en) | Hemostatic foam | |
| US20170246339A1 (en) | Novel hemostatic compositions and dressings for bleeding | |
| JP2003531850A (en) | Hemostatic, blood coagulant application method, blood coagulant base | |
| HUT67693A (en) | Hemostatic composition for arresting local bleedings | |
| Borten et al. | Recurrent anaphylactic reaction to intraperitoneal dextran 75 used for prevention of postsurgical adhesions | |
| CN105056285B (en) | It is a kind of can adhesion organization crack growth factor combine dressing and preparation method thereof | |
| US20020192271A1 (en) | Method for causing local hemostasis and hemostatic composition for local hemostasis | |
| CN103394078A (en) | Self-pressurized multi-target collaborative hemostasis degradable hemostatic preparation for injury first aid | |
| CN113712921A (en) | Novel rapid local pain-relieving hemostatic and application thereof | |
| Kim et al. | Evaluation of a Novel collagen hemostatic matrix: Comparison of two hemostatic matrices in a rabbits jejunal artery injury model | |
| Park et al. | Era of bloodless surgery: spotlights on hemostasic materials and techniques | |
| CN111920824A (en) | A Chinese medicinal composition for treating wound | |
| CN101002934A (en) | Compound cardiografin slow-releasing preparation for treating posto-lymphatic fistula and pancreas fistula, and its preparing method | |
| McLean et al. | Gangrene following fracture treated with heparin, papaverine, and intermittent venous occlusion: Report of a case; reasons for using heparin | |
| CN114269350B (en) | Topical hemostatic compositions | |
| Schweitzer et al. | Acid debridement of burns with phosphoric-acid gel | |
| RU2789581C1 (en) | Single topical application hemostatic gel manufacturing method | |
| CN114028608B (en) | Rapid hemostatic dressing for trauma nursing and preparation method thereof | |
| RU2174398C2 (en) | Method of treatment and/or prophylaxis of invaded soft tissues of body | |
| AU2001227771B2 (en) | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen | |
| GLASSER et al. | Intra-arterial injection of penicillin for infections of the extremities: preliminary report | |
| Hengrasmee et al. | Hemostatic agents in laparoscopic surgery | |
| Laumeiste, BS, Jessen, LM and Barone | Postsurgical wound care |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |